SCHEMBL26096339

SCHEMBL26096339

CSC1=N/C(=C\c2ccc3ncoc3c2)C(=O)N1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.56
▸ CYP1A2 P05177 2/20 0.55
▸ CYP3A4 P08684 2/20 0.55
▸ CYP2C19 P33261 2/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ CBS P35520 1/20 0.55
▸ DYRK2 Q92630 11/20 0.46
▸ DYRK1A Q13627 8/20 0.46
▸ DYRK3 O43781 7/20 0.46
▸ DYRK1B Q9Y463 7/20 0.46
▸ PIM1 P11309 4/20 0.46
▸ CLK1 P49759 7/20 0.42
▸ CLK4 Q9HAZ1 6/20 0.42
▸ CLK2 P49760 5/20 0.41
▸ GSK3B P49841 4/20 0.41
▸ DYRK4 Q9NR20 4/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ LTB4R Q15722 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26107614 0.81 MAPT (0.61) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL30494101 0.78 MAPT (0.57) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL26096313 0.78 MAPT (0.57) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL30396066 0.77 MAPT (0.56) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL26106872 0.77 MAPT (0.60) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL30363432 0.77 MAPT (0.60) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL26094464 0.77 MAPT (0.56) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL26103947 0.76 MAPT (0.55) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL30363334 0.76 MAPT (0.55) MAPTCYP1A2CYP3A4CYP2C19CYP2C9
SCHEMBL26093284 0.75 MAPT (0.57) MAPTCYP1A2CYP3A4CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 — — US disclosed
EP-4422753-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2024-09-04 — — EP disclosed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed
EP-4173675-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-05-03 — — EP disclosed
EP-4173675-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-05-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 CLK1, CLK2, CLK3 MAPT 312/4885CYP1A2 3737/4885CYP3A4 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback